Terminated PHASE2 INTERVENTIONAL 1-arm NCT04211922

Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

A Phase II, Multicenter, Single-arm Study to Evaluate Safety and Efficacy of Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Conditions ALK-positive Non-small Cell Lung Cancer

Interventions Alkotinib Capsules

Updated 10 times since 2020 Last updated: Apr 25, 2024 Started: Jan 21, 2020 Primary completion: Oct 11, 2022 Completion: Oct 11, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor R\&D Strategy Adjustment

Other terminated trials from Suzhou Zelgen Biopharmaceuticals Co.,Ltd

More terminations from Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Other ALK-positive Non-small Cell Lung Cancer trials with similar outcome

NCT02513667 · Phase PHASE2 · May 2021

Browse all ALK-positive Non-small Cell Lung Cancer trials

This PHASE2 trial investigates ALK-positive Non-small Cell Lung Cancer and is currently terminated or withdrawn. Suzhou Zelgen Biopharmaceuticals Co.,Ltd leads this study, which shows 10 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
May 2024 — Jul 2024 [monthly]

Terminated PHASE2

Status: Recruiting → Terminated
Nov 2023 — May 2024 [monthly]

Recruiting PHASE2
Dec 2022 — Nov 2023 [monthly]

Recruiting PHASE2

▶ Show 5 earlier versions

Sep 2021 — Dec 2022 [monthly]

Recruiting PHASE2
Jan 2021 — Sep 2021 [monthly]

Recruiting PHASE2
Aug 2020 — Jan 2021 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Feb 2020 — Aug 2020 [monthly]

Not Yet Recruiting PHASE2
Jan 2020 — Feb 2020 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Data source: Suzhou Zelgen Biopharmaceuticals Co.,Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China